timothy sykes logo

Stock News

MannKind’s Stock Plummets as United Therapeutics Introduces Tresmi Inhaler

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 2/26/2026, 11:33 am ET 2/26/2026, 11:33 am ET | 5 min 5 min read
MannKind’s Stock Plummets as United Therapeutics Introduces Tresmi Inhaler Thumbnail

A negative trend for MannKind Corporation persists as stocks have been trading down by -10.43 percent.

Candlestick Chart

Live Update At 11:33:24 EST: On Thursday, February 26, 2026 MannKind Corporation stock [NASDAQ: MNKD] is trending down by -10.43%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In terms of MannKind’s latest financial performance, recent reports have indicated both highs and lows. The revenue stood at approximately $285.50M, and the gross margin was impressively reported at 84.6%. This suggests that MannKind has done an excellent job in managing its production costs. However, there are areas of concern, notably the negative pretax profit margin of -16.6% and a PE ratio of 55.7, suggesting that the stock may be overvalued relative to its earnings. On top of this, financial statements reveal that MannKind has a current ratio of 3.3, suggesting a strong position in terms of their ability to cover short-term obligations.

Upon reviewing MannKind’s trading data, it’s clear that both short and long-term investors will be keeping a close eye on the market response to the Tresmi inhaler development. Shares opened at $3.70 on Feb 26, 2026, which fell significantly to close at $3.13, reflecting the general unease and reactions post-announcement.

Market Reactions to Competitive Pressures: An In-Depth Look

The introduction of Tresmi by United Therapeutics marks a significant milestone, and possibly a turning point in the respiratory treatment market. Previously, MannKind’s Tyvaso DPI had the upper hand, but the launch of Tresmi, a potential game-changer in inhaler technology due to its soft-mist delivery, can drastically alter the playing field.

Investors and market watchers are closely monitoring this development. The key concern revolves around the effectiveness of Tresmi compared to Tyvaso DPI. If Tresmi delivers equivalent or improved therapeutic benefits, MannKind might face stiff competition, which it seems unprepared for, due to its non-participation in Tresmi’s development.

The stock’s drop exhibits the fears of the market. The valuation, post this announcement, appears more speculative, feeding into the volatility usually associated with tech and health sectors. Conversing with market analysts showcases a diverse viewpoint: while some predict a short-term strain on MannKind’s financials, others maintain an optimistic long-term outlook based on company fundamentals and remaining portfolio.

From the financial data and current expenses related to research and general management, it is evident that MannKind needs to innovate or diversify its product line to combat the competitive heat. The enterprise value of $934.62M emphasizes the company’s potential in the broader scope of innovation in pharmaceutical inhalation therapy, yet the PE ratio alludes to caution when considering future financial projections.

More Breaking News

Conclusion: Roadmap to Navigating Future Challenges

In conclusion, MannKind currently faces notable headwinds due to the imminent competition presented by United Therapeutics’ Tresmi inhaler. This news has stirred the market, affecting stock prices and shaking trader confidence. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” MannKind will have to reassess its approach and possibly revamp its strategy to remain competitive. Equally important will be how the management leverages its current offerings and repositions itself to capture new opportunities or counteract potential losses from its Tyvaso DPI line. Adapting to the rapidly evolving market conditions might prove challenging, yet it also offers an opportunity for renaissance; whether MannKind capitalizes on this remains to be seen. Nonetheless, they must focus on infusing innovation, perhaps in areas not directly competing with their established products, to nurture growth while maintaining trader trust.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”